Submitted by Anonymous (not verified) on 20 August 2025 - 12:49
Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 4, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 4, Status: Authorised